Literature DB >> 32682872

Advances in novel molecular targets for antidepressants.

Qingzhong Wang1, Yogesh Dwivedi2.   

Abstract

Depression is the most common psychiatric illness affecting numerous people world-wide. The currently available antidepressant treatment presents low response and remission rates. Thus, new effective antidepressants need to be developed or discovered. Aiming to give an overview of novel possible antidepressant drug targets, we summarized the molecular targets of antidepressants and the underlying neurobiology of depression. We have also addressed the multidimensional perspectives on the progress in the psychopharmacological treatment of depression and on the new potential approaches with effective drug discovery.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressant; Anxiolytics; Depression; Novel targets

Mesh:

Substances:

Year:  2020        PMID: 32682872      PMCID: PMC7484229          DOI: 10.1016/j.pnpbp.2020.110041

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  209 in total

1.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Authors:  Shigeyuki Chaki; Ryoko Yoshikawa; Shiho Hirota; Toshiharu Shimazaki; Maoko Maeda; Naoya Kawashima; Takao Yoshimizu; Akito Yasuhara; Kazunari Sakagami; Shigeru Okuyama; Shigetada Nakanishi; Atsuro Nakazato
Journal:  Neuropharmacology       Date:  2004-03       Impact factor: 5.250

Review 2.  NMDA receptors and schizophrenia.

Authors:  Lars V Kristiansen; Ibone Huerta; Monica Beneyto; James H Meador-Woodruff
Journal:  Curr Opin Pharmacol       Date:  2006-11-09       Impact factor: 5.547

3.  The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.

Authors:  Guy Griebel; Sandra Beeské; Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2012-10-16       Impact factor: 4.384

Review 4.  PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.

Authors:  Juan M Zolezzi; Manuel J Santos; Sussy Bastías-Candia; Claudio Pinto; Juan A Godoy; Nibaldo C Inestrosa
Journal:  Biol Rev Camb Philos Soc       Date:  2017-02-20

5.  Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715).

Authors:  R T Layer; P Popik; T Olds; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  1995-11       Impact factor: 3.533

6.  Depressive- and anxiety-like behaviors and stress-related neuronal activation in vasopressin-deficient female Brattleboro rats.

Authors:  Anna Fodor; Krisztina Bea Kovács; Diána Balázsfi; Barbara Klausz; Ottó Pintér; Kornél Demeter; Nuria Daviu; Cristina Rabasa; David Rotllant; Roser Nadal; Dóra Zelena
Journal:  Physiol Behav       Date:  2016-03-03

7.  The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression.

Authors:  Laura Jiménez-Sánchez; Leticia Campa; Yves P Auberson; Albert Adell
Journal:  Neuropsychopharmacology       Date:  2014-05-29       Impact factor: 7.853

8.  The role of ketamine in treatment-resistant depression: a systematic review.

Authors:  Gianluca Serafini; Robert H Howland; Fabiana Rovedi; Paolo Girardi; Mario Amore
Journal:  Curr Neuropharmacol       Date:  2014-09       Impact factor: 7.363

9.  Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.

Authors:  Maurizio Fava; Michael E Thase; Madhukar H Trivedi; Elliot Ehrich; William F Martin; Asli Memisoglu; Narinder Nangia; Arielle D Stanford; Miao Yu; Sanjeev Pathak
Journal:  Mol Psychiatry       Date:  2018-10-29       Impact factor: 15.992

10.  Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.

Authors:  Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2020-02-24       Impact factor: 7.853

View more
  3 in total

1.  Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood.

Authors:  Yue-Ting Deng; Ya-Nan Ou; Bang-Sheng Wu; Yu-Xiang Yang; Yan Jiang; Yu-Yuan Huang; Yi Liu; Lan Tan; Qiang Dong; John Suckling; Fei Li; Jin-Tai Yu
Journal:  Mol Psychiatry       Date:  2022-03-16       Impact factor: 13.437

2.  Jasmine Tea Attenuates Chronic Unpredictable Mild Stress-Induced Depressive-like Behavior in Rats via the Gut-Brain Axis.

Authors:  Yangbo Zhang; Jianan Huang; Yifan Xiong; Xiangna Zhang; Yong Lin; Zhonghua Liu
Journal:  Nutrients       Date:  2021-12-27       Impact factor: 5.717

3.  Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.

Authors:  Shiau-Shian Huang; Hsi-Han Chen; Jui Wang; Wei J Chen; Hsi-Chung Chen; Po-Hsiu Kuo
Journal:  BMC Psychiatry       Date:  2020-11-17       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.